TB Alliance
New York, New York, United States
Purpose
to support the Shortening Treatments by Advancing Novel Drugs (STAND) trial, which is the first Phase III registration trial testing a drug regimen for use against both Tuberculosis and multidrug-resistant Tuberculosis (MDR-TB)
Division
Global Health
Date
November 2014
Region Served
GLOBAL
Committed amount
$7,469,911
Grant topic
Tuberculosis
Duration (months)
50
Grantee location
New York, New York, United States
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.